Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/31777

Eficacia a largo plazo del tratamiento con inhibidores de PCSK9 en pacientes con cardiopatcardiopatía isquémica


Vista previa

Ver/Abrir:
 TFG Gloria Luna Cañadas.pdf

1,92 MB
Adobe PDF
Compartir:
Título :
Eficacia a largo plazo del tratamiento con inhibidores de PCSK9 en pacientes con cardiopatcardiopatía isquémica
Autor :
Luna Cañadas, Gloria
Tutor:
Bertomeu González, Vicente
Cordero Fort, Alberto
Editor :
Universidad Miguel Hernández
Departamento:
Departamentos de la UMH::Medicina Clínica
Fecha de publicación:
2024-01-18
URI :
https://hdl.handle.net/11000/31777
Resumen :
La cardiopatía isquémica es una enfermedad caracterizada por el disbalance entre el aporte y la oferta de oxígeno al miocardio. En la mayoría de los casos la causa de la oclusión de las arterias coronarias es la rotura de la placa aterosclerótica cuya composición principal es LDL y leucocitos. Esta...  Ver más
Ischaemic heart disease is a disease characterised by an imbalance between the supply and demand of oxygen to the myocardium. In most cases the cause of coronary artery occlusion is the rupture of atherosclerotic plaque whose main composition is LDL and le ukocytes. This pathology is one of the leading causes of death worldwide, causing 9,44 million deaths in 2021. Although the incidence has decreased considerably in recent years, it is still a major health problem due to its high mortality and the social an d health impact of the disease. PCSK9 inhibitors have been a revolution in the preventive treatment of ischaemic heart disease, as they have been shown in the ODYSSEY and FOURIER FOURIER-OLE trials to be effective in reducing LDLc levels in patients who did not respond adequately to treatment af ter ACS. It should be noted that these drugs have not only proven their efficacy but also their safety, as no serious effects were reported during their use. In addition, during this analysis it was possible to determine the profile of the patients who performed best after starting treatment. Also, the incidence of adverse cardiovascular effects and the factors that are linked to these and how PCSK9 inhibitors decrease this risk were determined. Therefore, the aim of this study was to carry out a systematic review of the effect of PCSK9 inhibitors in patients with ischaemic heart disease.
Palabras clave/Materias:
cardiopatía isquémica
hipercolesterolemia
inhibidores del PCSK9
Área de conocimiento :
CDU: Ciencias aplicadas
Tipo de documento :
info:eu-repo/semantics/bachelorThesis
Derechos de acceso:
info:eu-repo/semantics/openAccess
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Aparece en las colecciones:
TFG - Farmacia



Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.